Immunization News and Research

RSS

Childhood immunization rates in Texas declined sharply during COVID-19 pandemic

Despite expert recommendations that children continue to get regularly scheduled vaccines during the pandemic, vaccination rates have decreased in several states.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Scientists have recently investigated the dynamics of immune responses in elderly people who have received two doses of the Pfizer/BioNTech COVID-19 vaccine.

19 May 2021

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Sequentia Biotech and NextBiomics announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.

From Sequentia Biotech 19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Researchers from Germany and the USA recently investigated the cellular and humoral immune responses of patients with IMIDs on immunomodulatory treatment to mRNA COVID-19 vaccines. The research is published on the medRxiv* preprint server.

19 May 2021

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19, the coronavirus disease of 2019, is one of the worst pandemics in human history. It emerged in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nearly 164 million SARS-CoV-2 infections and 3.4 million deaths have been reported globally since the beginning of the pandemic, which is still raging in many countries.

18 May 2021

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Researchers in Germany have demonstrated the preclinical effectiveness of a next-generation coronavirus disease 2019 (COVID-19) vaccine at enhancing antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 May 2021

What does approval of the Pfizer vaccine for teens and preteens mean for my child?

Extending the emergency use of the Pfizer-BioNTech vaccine to preteens and young adolescents adds nearly 17 million more Americans to the pool of those eligible to be immunized against covid-19, helping to build a vaccinated population closer to herd immunity. Moderna and Johnson & Johnson are also testing the efficacy of their vaccines in teens and children.

14 May 2021

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

In a recent bioRxiv* preprint research paper, M. Gordon Joyce et al. designed engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 and receptor-binding domain (RBD). They demonstrated that these immunogens induced robust S-binding, ACE2 (angiotensin-converting enzyme)-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2 in mice.

13 May 2021

Dominance of South African SARS-CoV-2 variant in the US is unlikely but possible

Researchers in the United States and Canada have conducted a study showing that the South African variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – is unlikely to become the dominant strain in the US.

13 May 2021

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

A recent report on the medRxiv* preprint server suggests that a single dose of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine could elicit higher titers of neutralizing antibodies, effectively acting as a booster dose, in people who have already been infected by the SARS-CoV-2.

13 May 2021

Rheumatologists develop a set of consensus statements on COVID-19 vaccination

Rheumatologists in Hong Kong joined hands to develop a set of consensus statements on COVID-19 vaccination for local adult patients with autoimmune rheumatic diseases. These timely statements would serve to be a guide for rheumatologists, other specialists, family physicians, specialty nurses, and the public regarding COVID-19 vaccination for patients with rheumatic diseases.

13 May 2021

Personalized vaccine can provide effective immunization against cancer

Marie-Claude Bourgeois-Daigneault and her team at the CRCHUM are using mice to show how a combination of peptides and oncolytic viruses, used as an adjuvant, can provide effective immunization against cancer.

11 May 2021

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.

10 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

SARS-CoV-2 infection prolongs viral shedding and lymphocyte loss in patients with cancer

Patients with cancer have a more challenging time with infections while undergoing treatment — placing them as high-risk for severe COVID-19 illness and death. However, how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts with cancer therapies remains poorly understood.

7 May 2021

Israeli study shows real-world efficacy of Pfizer-BioNTech’s COVID-19 vaccine

Researchers have conducted an analysis of nationwide surveillance data from Israel demonstrating the real-world effectiveness of Pfizer-BioNTech’s BNT162b2 vaccine at protecting against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

6 May 2021

Indian SARS-CoV-2 variant shows enhanced host cell entry and immune evasion

A study conducted by researchers in Germany has found that the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has emerged in India entered certain types of lung and intestine cells with slightly increased efficiency compared with the original wild-type strain.

6 May 2021

India's successful program to eliminate polio provides guidance for mass immunization initiatives

As India urgently scales up its vaccination campaign for the COVID-19 virus, a new study which examined the country's successful program to eliminate polio provides guidance on how this and future mass immunization campaigns can be successful, especially in vaccinating hard to reach groups.

6 May 2021

Immunization News and Research

Childhood immunization rates in Texas declined sharply during COVID-19 pandemic

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

What does approval of the Pfizer vaccine for teens and preteens mean for my child?

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

Dominance of South African SARS-CoV-2 variant in the US is unlikely but possible

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

Rheumatologists develop a set of consensus statements on COVID-19 vaccination

Personalized vaccine can provide effective immunization against cancer

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

SARS-CoV-2 infection prolongs viral shedding and lymphocyte loss in patients with cancer

Israeli study shows real-world efficacy of Pfizer-BioNTech’s COVID-19 vaccine

Indian SARS-CoV-2 variant shows enhanced host cell entry and immune evasion

India's successful program to eliminate polio provides guidance for mass immunization initiatives

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News